About

Matt Blischak is the Chief Executive Officer of Finch Therapeutics. Matt has more than 20 years experience as an executive in the life sciences industry with a particular focus on high stakes patent litigation related to multiple blockbuster drugs. He has also been involved in significant licensing, acquisition, collaboration, and litigation settlement agreements over that time. Before joining Finch, Matt served at Roivant Sciences where he focused on the management and protection of intellectual property for the company and its subsidiaries. Matt directed patent enforcement on a global scale for Bristol-Myers Squibb Co., Teva Pharmacueticals, and Sunovion Pharmaceuticals. His legal career began at Cleary, Gottlieb, Steen and Hamilton.

Matt received a bachelor of science in chemical engineering from Case-Western Reserve University, a masters degree in biotechnology from Johns Hopkins University, and a law degree from The American University Washington College of Law.

Lance Thibault is the Chief Financial Officer of Finch Therapeutics. Lance currently serves as a Managing Director at Danforth Advisors, where he brings more than 30 years of experience in the life sciences industry to his work for Danforth clients. Prior to joining Danforth, he spent ten years as CFO leading a US public biotech company. He previously spent 12 years with PricewaterhouseCoopers, where he was an integral member of the Transaction Advisory Services Global Capital Markets Group in London, England. Lance is a CPA and holds a BS in Accountancy from Bentley University.